Prasinezumab

DRUG3 trials

Sponsors

Hoffmann-La Roche, University Hospital Tuebingen

Conditions

Parkinson's DiseaseParkinsons Disease

Phase 2

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Active, not recruitingNCT04777331

Hoffmann-La RocheParkinsons Disease

Start: 2021-05-05End: 2031-06-30Updated: 2026-09-04

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

Not yet recruitingNCT07055087

University Hospital TuebingenParkinson's Disease

Start: 2025-12-31End: 2031-05-31Target: 120Updated: 2025-07-08

Phase 3

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

RecruitingNCT07174310

Hoffmann-La RocheParkinson's Disease

Start: 2025-11-24End: 2031-06-30Target: 900Updated: 2026-09-03

Related Papers

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

2024-12-295 citations

Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Nature Medicine2024-10-0830 citations